Archive for March, 2011

« Previous Entries

FDA approves new drug Yervoy for melanoma treatment

Wednesday, March 30th, 2011

The Food and Drug Administration (FDA) has finally given approval to a drug named Yervoy that has shown evidence of prolonging lives of patients with melanoma, a type of skin cancer. Yervoy, also known as ipilimumab, is a new drug manufactured by Bristol-Myers Squibb Co. (BMY). The drug combats melanoma by allowing the immune system […]

Rich white women at a greater risk of developing melanoma

Monday, March 28th, 2011

A recent study has found that affluent young white women are six times more prone to melanoma, a lethal skin cancer, as compared to relatively less affluent woman. The study, which analyzes skin cancer cases in California, attributes the findings to the likelihood of affluent young women spending more time in tanning salons and going […]

Gilenya: The new oral medication for multiple sclerosis

Monday, March 28th, 2011

Here is some good news for the 55, 000 – 75, 000 Canadians who are affected every year by the debilitating disease called multiple sclerosis. Finally, one can put an end to the painful processes of having to take their medication with the help of a syringe or the numerous infusion therapies like suppository or […]

Xolair helps children in overcoming milk intolerance

Sunday, March 27th, 2011

A new study suggests that allergy medication Xolair may be helpful in developing milk tolerance in children who are allergic to milk products. The study found that a method called sensitization, in which a child’s exposure to a food he/she is allergic to is gradually increased, is facilitated by the use of Xolair. Sensitization is […]

Longer treatment with Tamoxifen reduces risks of cancer recurrence

Friday, March 25th, 2011

New research has found that a 5-year course of the breast cancer drug Tamoxifen works better than a 2-year course of the drug. The study, the results of which were published online in the Journal of Clinical Oncology, was conducted by scientists at the Cancer Research UK. The results have once again pointed out the […]

Drug prices continue to rise in U.S.: Barclays study

Wednesday, March 23rd, 2011

According to an analysis by the investment bank Barclays Capital, prices of brand-name drugs continue to skyrocket despite attempts by the federal and state government to contain healthcare costs. The Wall Street Journal reports that the study analyzed the prices of around 130 brand-name drugs, including insulin for diabetes and injectables for rheumatoid arthritis. It […]

Alzheimers: a battle for 5 million sufferers and 15 million unpaid caregivers in the US

Saturday, March 19th, 2011

The rising number of people suffering from Alzheimer’s disease is also accounting for a rise in number of unpaid caregivers in the country. A disclosure made by Alzheimer’s experts of the Alzheimer’s Association on Tuesday, states that out an astounding 15 million people take care of a loved one suffering from Alzheimer’s disease or similar […]

Study: Demand for expensive prostate cancer treatments on the rise

Friday, March 18th, 2011

Prostate cancer is one of the most common cancers in the US. 180,000 American men are diagnosed with prostate cancer every year. As a result, the demand and popularity of prostate cancer treatments with latest technologies is increasing day by day. Not surprisingly, these treatment options come with a hefty price tag. However, the price […]

Brand-Name Drug Prices Surpass Other Medical Costs: GAO Report

Thursday, March 17th, 2011

The non-partisan US Government Accountability Office (GAO) has reported that prices for brand-name prescription drugs in the US have risen at a faster rate as compared to other medical goods and services over the last four years. According to the report, between 2006 and 2010 the average price of 100 commonly used drugs, including 45 […]

Olmesartan delays microalbuminuria onset in Type 2 diabetics

Tuesday, March 15th, 2011

Source: MedWire News Olmesartan therapy is able to delay the onset of microalbuminuria in patients with Type 2 diabetes, the ROADMAP trial has found. The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial was a double-blind multicenter study designed to test whether treatment with an angiotensin receptor blocker (ARB) would delay or prevent the occurrence […]

« Previous Entries